pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 28·1 min read
save

J&J offers $5.5 billion settlement to resolve talc lawsuits

Jul 28, 2026·read at Endpoints ↗DealNeutral

Johnson & Johnson has put forward a settlement proposal of $5.5 billion to end the litigation over its talc products.

The proposal follows more than a decade of legal battles and three unsuccessful attempts by the company to use bankruptcy to resolve the claims.

If accepted, the deal would bring finality to the talc saga that has cost the company significant legal expenses and reputational damage.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “J&J proposes $5.5B talc settlement”

read at Endpoints ↗
76 words · retrieved Jul 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOHNSON & JOHNSON2
drugs
talc6

related stories

  • Oct 13J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentBioSpace
  • Jun 4Parabilis Medicines charts $413M IPO to back peptide pipelineEndpoints
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive
  • Jun 1#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainEndpoints
  • Jun 12026 Orphan Drugs Report: A safe(r) passage amid stormy waters?BioPharma Dive